Neurofibrillary tangles (NFTs) composed of intracellular aggregates of tau protein are a key neuropathological feature of Alzheimer’s Disease (AD) and other neurodegenerative diseases, collectively termed tauopathies. The abundance of NFTs has been reported to correlate positively with the severity of cognitive impairment in AD. However, accumulating evidences derived from studies of experimental models have identified that NFTs themselves may not be neurotoxic. Now, many of tau researchers are seeking a “toxic” form of tau protein. Moreover, it was suggested that a “toxic” tau was capable to seed aggregation of native tau protein and to propagate in a prion-like manner. However, the exact neurotoxic tau species remain unclear. Because mature tangles seem to be non-toxic component, “tau oligomers” as the candidate of “toxic” tau have been investigated for more than one decade. In this topic, we will discuss our consensus of “tau oligomers” because the term of “tau oligomers” [e.g. dimer (disulfide bond-dependent or independent), multimer (more than dimer), granular (definition by EM or AFM) and maybe small filamentous aggregates] has been used by each researchers definition. From a biochemical point of view, tau protein has several unique characteristics such as natively unfolded conformation, thermo-stability, acid-stability, and capability of post-translational modifications. Although tau protein research has been continued for a long time, we are still missing the mechanisms of NFT formation. It is unclear how the conversion is occurred from natively unfolded protein to abnormally mis-folded protein. It remains unknown how tau protein can be formed filaments [e.g. paired helical filament (PHF), straight filament and twisted filament] in cells albeit in vitro studies confirmed tau self-assembly by several inducing factors. Researchers are still debating whether tau oligomerization is primary event rather than tau phosphorylation in the tau pathogenesis. Inhibition of either tau phosphorylation or aggregation has been investigated for the prevention of tauopathies, however, it will make an irrelevant result if we don’t know an exact target of neurotoxicity. It is a time to have a consensus of definition, terminology and methodology for the identification of “tau oligomers”.

Photobiomodulation in the Brain: Low-Level Laser (Light) Therapy in Neurology and Neuroscience presents the fundamentals of photobiomodulation and the diversity of applications in which light can be implemented in the brain. It will serve as a reference for future research in the area, providing the basic foundations readers need to understand photobiomodulation's science-based evidence, practical applications and related adaptations to specific therapeutic interventions. The book covers the mechanisms of action of photobiomodulation to the brain, and includes chapters describing the pre-clinical studies and clinical trials that have been undertaken for diverse brain disorders, including traumatic events, degenerative diseases and psychiatric disorders. - Provides a much-needed reference on photobiomodulation with an unprecedented focus on the brain and its disorders - Features a body of world-renowned editors and chapter authors that promote research, policy and funding - Discusses the recent and rapid accumulation of literature in this area of research and the shift towards the use of non-invasive techniques in therapy

Offers answers to challenges in clinical immunology. This book contains immunology knowledge and includes a companion web site to give you two ways to find the answers you need.

The editor of this volume, having research interests in the field of ROS production and the damage to cellular systems, has identified a number of enzymes showing ·OH scavenging activities details of which are anticipated to be published in the near future as confirmatory experiments are awaited. It is hoped that the information presented in this book on NDs will stimulate both expert and novice researchers in the field with excellent overviews of the current status of research and pointers to future research goals. Clinicians, nurses as well as families and caregivers should also benefit from the material presented in handling and treating their specialised cases. Also the insights gained should be valuable for further understanding of the diseases at molecular levels and should lead to development of new biomarkers, novel diagnostic tools and more effective therapeutic drugs to treat the clinical problems raised by these devastating diseases.

We would like to acknowledge and thank Francesco Petrillo, Carlo Gesualdo, Chiara Bianca Maria Platania and Maria Consiglia Trottafor their support on the collection’s Editorial article.